Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (21-30 of 162) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|March 8, 2016
Present and future of molecular monitoring in chronic myeloid leukaemiaSimona Soverini, Caterina De Benedittis, Manuela Mancini, et al.
Pharmacological Research|February 11, 2018
Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysisSarah Cargnin, Gloria Ravegnini, Simona Soverini, et al.
Hemasphere|March 21, 2022
Current treatment approaches in CMLFausto Castagnetti, Gabriele Gugliotta, Simona Soverini, et al.
The Oncologist|June 3, 2011
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?Simona Soverini, Gianantonio Rosti, Ilaria Iacobucci, et al.
Molecular Cancer|February 20, 2018
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySimona Soverini, Manuela Mancini, Luana Bavaro, et al.
Pharmacogenomics|August 28, 2012
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysisSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Haematologica|April 12, 2005
New tyrosine kinase inhibitors in chronic myeloid leukemiaGiovanni Martinelli, Simona Soverini, Gianantonio Rosti, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Response definitions and European Leukemianet Management recommendationsMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Journal of Clinical Medicine|June 6, 2020
Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and PerspectivesDomenico Russo, José Valentín Garcia-Gutierrez, Simona Soverini, et al.
International Journal of Molecular Sciences|July 2, 2021
Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?Simona Soverini, Sara De Santis, Cecilia Monaldi, et al.
Pageof 17

Showing results (21-30 of 162) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|March 8, 2016
Present and future of molecular monitoring in chronic myeloid leukaemiaSimona Soverini, Caterina De Benedittis, Manuela Mancini, et al.
Pharmacological Research|February 11, 2018
Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysisSarah Cargnin, Gloria Ravegnini, Simona Soverini, et al.
Hemasphere|March 21, 2022
Current treatment approaches in CMLFausto Castagnetti, Gabriele Gugliotta, Simona Soverini, et al.
The Oncologist|June 3, 2011
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?Simona Soverini, Gianantonio Rosti, Ilaria Iacobucci, et al.
Molecular Cancer|February 20, 2018
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapySimona Soverini, Manuela Mancini, Luana Bavaro, et al.
Pharmacogenomics|August 28, 2012
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysisSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Haematologica|April 12, 2005
New tyrosine kinase inhibitors in chronic myeloid leukemiaGiovanni Martinelli, Simona Soverini, Gianantonio Rosti, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Response definitions and European Leukemianet Management recommendationsMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Journal of Clinical Medicine|June 6, 2020
Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and PerspectivesDomenico Russo, José Valentín Garcia-Gutierrez, Simona Soverini, et al.
International Journal of Molecular Sciences|July 2, 2021
Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?Simona Soverini, Sara De Santis, Cecilia Monaldi, et al.
Pageof 17